Results 101 to 110 of about 31,870 (205)
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia.
Mercedes Del Pilar Mahecha +15 more
core +1 more source
The effects of host-vector relationships and density dependence on the epidemiology of visceral leishmaniasis [PDF]
In Latin America, visceral leishmaniasis (VL) is caused by infection with Leishmania infantum, an endemic but lethal parasite transmitted by Lutzomyia longipalpis sandflies.
Dilger, Erin
core
Miltefosine: issues to be addressed in the future.
Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice ...
Berman, J +19 more
core +1 more source
Immunity and immunosuppression in experimental visceral leishmaniasis
Leishmaniasis is a disease caused by protozoa of the genus Leishmania, and visceral leishmaniasis is a form in which the inner organs are affected. Since knowledge about immunity in experimental visceral leishmaniasis is poor, we present here a review on
Goto H., Lindoso J.A.L.
doaj
Visceral leishmaniasis and AIDS [PDF]
M, de Gorgolas, M A, Miles
openaire +2 more sources
Dyserythropoiesis in visceral leishmaniasis [PDF]
openaire +2 more sources
Spatial distribution of canine visceral leishmaniasis and its relationship with human visceral leishmaniasis in a municipality of Rio de Janeiro, Brazil. [PDF]
Gonçalves AEOP +9 more
europepmc +1 more source
Visceral leishmaniasis risk clusters on Brazil's borders: 2013 to 2022. [PDF]
Moreira WDC +6 more
europepmc +1 more source
A Case of Visceral Leishmaniasis in an Immunocompetent Adult. [PDF]
Coelho J +4 more
europepmc +1 more source

